Feraccru granted major extension to approval in Switzerland

London, UK, 24th April 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now include treatment of all adults with iron deficiency (ID) with or without anaemia.

This follows an equivalent broadening of the marketing authorisation approval for Feraccru® in the European Union in 2018 and futher increases the commercial opportunity for Feraccru®, which was initially approved in both the EU and Switzerland just for the treatment of iron deficiency anemia (IDA) in adult patients with inflammatory bowel disease (IBD).

Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: "We are delighted with the positive progress we continue to make with regulatory authorities in relation to maximising the commercial opportunity for Feraccru®. Switzerland represents an attractive market opportunity as it is both well reimbursed and has a much higher level of treatment penetration compared to other markets, particularly for IV iron therapies.

"Together with the new label, we expect the recent positive result from the AEGIS-H2H phase 3b active comparator study of Feraccru® versus intravenously delivered Ferinject® will have added importance and will provide an enhanced commercial opportunity to Ewo, our Swiss commercial partner. We look forward to working with them to deliver commercial success for Feraccru® in Switzerland at the earliest opportunity."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.